Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The liver and methotrexate].

D Laharie1, E Terrebonne, J Vergniol

  • 1Centre d'investigation de la fibrose hépatique, hôpital Haut-Lévêque, 33604 Pessac cedex, France.

Gastroenterologie Clinique Et Biologique
|May 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of severe acute alcoholic hepatitis in France: results of a national survey: R1.

Clinics and research in hepatology and gastroenterology·2026
Same author

COVID-19 and chronic liver disease: results from the 1219 patients French registry.

Scientific reports·2025
Same author

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.

The American journal of gastroenterology·2025
Same author

Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: A propensity-score matched comparative analysis.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

[What to do when faced with a chronic elevation of transaminases].

La Revue de medecine interne·2023
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
Same journal

[Not Available].

Gastroenterologie clinique et biologique·2014
See all related articles

Methotrexate can cause liver fibrosis in patients with inflammatory conditions. However, factors like alcohol, diabetes, and obesity may contribute more significantly to liver damage than the drug itself.

Area of Science:

  • Pharmacology
  • Hepatology
  • Immunology

Context:

  • Methotrexate is a common treatment for inflammatory diseases like rheumatoid arthritis, psoriasis, and Crohn's disease.
  • Liver toxicity, specifically liver fibrosis, is a known risk associated with prolonged methotrexate use.
  • Co-existing conditions such as alcohol consumption, diabetes, and obesity are frequently observed in patients developing methotrexate-associated liver fibrosis.

Purpose:

  • To investigate the role of methotrexate in liver fibrosis development.
  • To differentiate between methotrexate-induced liver damage and fibrosis caused by associated risk factors.
  • To evaluate current monitoring and diagnostic recommendations for methotrexate-induced liver injury.

Summary:

  • Prolonged methotrexate therapy can lead to liver fibrosis.

Related Experiment Videos

  • The contribution of co-morbidities (alcohol, diabetes, obesity) to liver fibrosis in patients on methotrexate requires further investigation.
  • Liver biopsy is recommended for monitoring, particularly in psoriasis patients, but non-invasive methods like FibroScan warrant further study.

    • Impact:

    • Highlights the need for personalized monitoring strategies for methotrexate-treated patients.
    • Suggests that managing co-existing conditions may be crucial in preventing liver fibrosis.
    • Emphasizes the potential utility of non-invasive fibrosis assessment tools in clinical practice.